Op-Ed: The Angel Is in the Details

April 26, 2007

Twenty years ago, then-FDA Commissioner Frank Young and I began a Wall Street Journal op-ed thus: “Defining the terms ‘biotechnology’ and ‘genetic engineering’ isn’t an easy task, since the terms don’t represent natural groupings of processes or products. They connote something different to individual commentators, journalists, organizations, congressional staffers and members of the public. The terms are ambiguous, the source of much confusion and little advantage, and we would do well to return to more specific and descriptive terms.” (TCS Daily)